North America Angina Pectoris Drugs Market

North America Angina Pectoris Drugs Market Size (2024 to 2029)

The size of the North America Angina Pectoris Drugs Market is forecasted to grow at a promising CAGR from 2024 to 2029.

Factors such as sedentary lifestyle and obesity in the younger generation, the research and development of effective drugs, the high demand for specific and suitable drugs for the treatment of angina, and in countries developing, awareness of the cardiovascular disease is increasing, which in turn is driving the angina pectoris drugs market in the North American region.

In addition, the North American market will experience some trends, such as the introduction of new pharmacological agents, genomic drugs, and a growing trend towards strategic alliances and acquisitions. Heart disease and stroke statistics from the American Heart Association indicate that more than 9 million adults in the United States have chronic angina pectoris. The estimated annual risk of associated non-fatal myocardial infarction (MI) and death at 3.6% and 1.3-2.5%, respectively. The prevalence of angina increases dramatically with age in both sexes, varying between 2.5% and 5.2% in men aged 45 to 55 and 11.0% 21.0% in older men 65 to 75 years old and between 0.25% and 1.9% in women between 45 and 55 years old and 12.0%. 16.3% among women aged 65 to 75.

Further, the growing population of people with HF is the primary factor contributing to the market's growth. In addition, according to the WHO, ischemic heart disease (IC) is one of the ten leading causes of death worldwide. In addition, the high prevalence of chronic diseases such as diabetes, hypertension, and cholesterol levels further increase the risk of cardiovascular disease. Therefore, increased funding for the development of more advanced IHD drugs will help fuel the growth of the North American market. Other drivers include technological advances toward personalized cardiovascular drugs and the rise of new drug delivery systems.

The changing regulatory landscape in the United States is expected to impact clinical trials of advanced therapy drugs. For example, multiple gene therapy products are being tested in phase II and III studies as a novel way to address the demand for non-surgical cardiovascular therapies. For instance, Taxus Cardium's adenovector DNA (serotype 5) gene therapy is in advanced clinical studies, and the market might see significant development in the following years.

However, the availability of effective surgical treatments and catheter interventions may slow the market's growth. In addition, the increased competition in the generic version of drugs threatens market players.

This research report on the North America angina pectoris drugs market has been segmented and sub-segmented into the following categories.

North America Angina Pectoris Drugs Market By Therapeutic Class

Beta-Blockers, Calcium Antagonists, Anticoagulants, Anti-Platelets, and Others    

North America Angina Pectoris Drugs Market By Country

The United States, Canada, and the Rest of North AmericaThe Global Angina Pectoris drugs market was dominated by North America, with an overall market share of over 33% globally. The regional market growth is attributed to the presence of advanced healthcare infrastructure, technological advancements, and favorable reimbursement policies in the region.

The United States dominates the angina pectoris drugs market in North America during the forecast period due to the established healthcare infrastructure, increased adoption of therapeutics, and the presence of key manufacturers in the United States who are responsible for its significant part. IHD is one of the leading causes of death and disability, while angina is its most common symptom. It is estimated that 9.9 million patients in the United States suffer from angina and its treatment is complex. According to the CDC, in the United States, approximately 655,000 Americans die from heart disease each year. In addition, the increasing incidence of cardiac disorders due to sedentary lifestyles and favorable regulatory initiatives are driving the market's growth.

Canada is expected to experience promising growth during the forecast period due to increase per capita health spending, the rapid growth of the biopharmaceutical industry, and government initiatives to promote health care. Further, is it anticipated to contribute to the angina pectoris drugs in North America over the forecast period.

KEY MARKET PLAYERS

Some of the major companies dominating the market by their products and services include Sanofi, Bayer HealthCare, Cardeus Pharmaceuticals and CardioVascular BioTherapeutics (CVBT), Merck & Co. Inc., Anthera Pharmaceuticals, Cardium Therapeutics, Astellas Pharma, Ark Therapeutics Group plc, Torrent Pharmaceuticals Limited, Circ Pharma Limited, HUYA Bioscience International LLC, Lacer S.A., Viromed Co. Ltd., and Baxter Healthcare Corporation.